Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Paul J. Hampel(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Taimur Sher(Mayo Clinic in Florida), Min Shi(Mayo Clinic in Arizona), Sikander Ailawadhi(Jacksonville College), Ricardo Parrondo(Jacksonville College), Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Daniel L. Van Dyke(Mayo Clinic), Susan L. Slager(Mayo Clinic), Wei Ding(Mayo Clinic), Eli Muchtar(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Esteban Braggio(Dana-Farber Cancer Institute), Curtis A. Hanson(Toyota Motor Corporation (Switzerland)), Yucai Wang(Mayo Clinic), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Asher Chanan‐Khan(WinnMed)
Cited by 17
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727